The Center for Medicare and Medicaid Innovation under CMS expanded its value-based insurance design (VBID) model for Medicare Advantage, as well as created more risk sharing in Part D payment models for plan sponsors. Both plans are voluntary.
The Center for Medicare and Medicaid Innovation (CMMI) under CMS expanded its value-based insurance design (VBID) model for Medicare Advantage (MA), as well as created more risk sharing in Part D payment models for plan sponsors. Both plans are voluntary, CMS said.
CMS said the new MA model updates the VBID model that first launched in 2017, beginning in 7 states. With Friday’s announcement, the VBID model will be available in all 50 states, as required by the Bipartisan Budget Act of 2018. Interventions may encompass 1 or more areas:
Beginning in 2021, the VBID model will also pilot the Medicare hospice benefit in MA plans. In addition, CMS said it is extending the performance period of the VBID model by an additional 3 years, through 2024.
CMMI was created by the Obama administration with the notion that it could pilot new ways for Medicare and Medicaid to pay for care to save money and make the healthcare system more efficient. It is headed by Adam Boehler, the former CEO of Landmark Health.
On a call with reporters explaining the changes, a CMS official said the changes would save the government more than $2 billion per year.
The model for Part D plans is called the Part D Payment Modernization model and is linked to the president’s plan to lower drug prices, CMS Administrator Seema Verma said.
Currently, once a patient’s prescription drug spending is high enough for the patient to enter the final phase of the benefit, known as the “catastrophic phase,” Medicare is responsible for 80% of drug costs. Verma said this creates “perverse incentives” and leaves plans with little reason to negotiate lower costs for the highest-spending patients.
From 2008 to 2017, she said, federal spending in the Part D catastrophic phase nearly quadrupled from $9.4 billion to $37.4 billion, about an average increase of 17% per year. In 2016, 3.2 million beneficiaries reached the Part D catastrophic phase, and the beneficiaries in catastrophic who did not qualify for the low-income subsidy faced average annual out-of-pocket drug costs of more than $3000.
Under the new model, which takes effect in 2020, participating plans will take on greater risk for spending in the catastrophic phase of Part D, creating new incentives for plans, patients, and providers to choose drugs with lower list prices. Also, the model introduces a Part D rewards and incentives program to align this model with the changes to VBID, and to provide Part D plans with additional tools to control drug costs and help enrollees in choosing drugs with lower list prices.
Based on plan-year performance, CMS will calculate a spending target for what governmental spending would have been without plans taking on this additional risk.
CMS also released the first year VBID model evaluation report. In 2017, 9 out of 23 eligible organizations within 3 of 7 eligible states chose to participate in the model, targeting chronic obstructive pulmonary disease, congestive heart failure, diabetes, and hypertension. More than 96,000 beneficiaries with specified target conditions were eligible for the VBID model; across all participating organizations, 61% of eligible beneficiaries actually received VBID benefits.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More